Pyxis Oncology (PYXS) Stock: Buy, Sell, or Hold?
PYXS - Pyxis Oncology, Inc. Common Stock
$2.19
-0.14 (-6.01%)
▼
5d:
-25.0%
30d:
-36.34%
90d:
-16.73%
WAIT
LOW Confidence
Analysis Updated: Oct 1, 2026 12:00 AM ET
Earnings: Nov 02, 2026
30d
Get Alerted When PYXS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: PYXS is down 25.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: PYXS is down 25.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: PYXS is currently trading at $2.19, which is considered oversold relative to its 30-day fair value range of $2.85 to $3.60.
Technical Outlook: Technically, PYXS is in a strong uptrend. Immediate support is located at $2.12, while resistance sits at $3.44. Short-term momentum is weak, with the stock down 6.0% recently.
Market Sentiment: PYXS scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $8.67 (+295.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, PYXS is in a strong uptrend. Immediate support is located at $2.12, while resistance sits at $3.44. Short-term momentum is weak, with the stock down 6.0% recently.
Market Sentiment: PYXS scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $8.67 (+295.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$2.85 -
$3.60
Company Quality Score
36/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
52.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (33/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-6.0%)
- BULLISH: Trading 295.7% below Wall St target ($8.67)
- WARNING: Composite score 36/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$2.85 -
$3.60
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$2.12
Resistance Level
$3.44
Current Trend
Strong Uptrend
Technical data as of
Oct 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.94
Wall Street Target
$8.67
(+295.7%)
Share & Embed Analysis
Last updated: October 02, 2026 8:10 AM ET
Data refreshes hourly during market hours. Next update: 9:10 AM
Data refreshes hourly during market hours. Next update: 9:10 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PYXS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 51 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1180 | 59 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$851 | 53 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$293 | 61 BUY |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$118 | 54 HOLD |
